Dear Valued Visitor,

We have noticed that you are using an ad blocker software.

Although advertisements on the web pages may degrade your experience, our business certainly depends on them and we can only keep providing you high-quality research based articles as long as we can display ads on our pages.

To view this article, you can disable your ad blocker and refresh this page or simply login.

We only allow registered users to use ad blockers. You can sign up for free by clicking here or you can login if you are already a member.

Filing Details

Accession Number:
0001209191-19-050079
Form Type:
4
Zero Holdings:
No
Publication Time:
2019-09-18 16:45:28
Reporting Period:
2019-09-16
Accepted Time:
2019-09-18 16:45:28
SEC Url:
Form 4 Filing
Issuer
Cik Name Symbol Sector (SIC) IRS No
1423824 Alder Biopharmaceuticals Inc ALDR Pharmaceutical Preparations (2834) 000000000
Insiders
Cik Name Reported Address Insider Title Director Officer Large Shareholder Other
1604800 L T Jeffrey Smith 11804 North Creek Parkway South
Bothell WA 98011
Managing Director No Yes No No
Reported Non-Derivative Transactions
Sec. Name Acquisiton - Disposition Date Amount Price Remaning Holdings Equity Swap Involved Form Type Code Nature of Ownership Explanation
Common Stock Acquisiton 2019-09-16 22,727 $4.46 27,999 No 4 M Direct
Common Stock Acquisiton 2019-09-16 10,001 $3.47 38,000 No 4 M Direct
Common Stock Disposition 2019-09-16 32,728 $18.44 5,272 No 4 S Direct
Equity Swap Involved Form Type Code Nature of Ownership Explanation
No 4 M Direct
No 4 M Direct
No 4 S Direct
Reported Derivative Transactions
Sec. Name Sec. Type Acquisiton - Disposition Date Amount Price Amount - 2 Price - 2
Common Stock Stock Option (Right to Buy) Disposition 2019-09-16 22,727 $0.00 22,727 $4.46
Common Stock Stock Option (Right to Buy) Disposition 2019-09-16 10,001 $0.00 10,001 $3.47
Remaning Holdings Exercise Date Expiration Date Equity Swap Involved Transaction Form Type Transaction Code Nature of Ownership
0 2020-02-25 No 4 M Direct
17,271 2022-06-12 No 4 M Direct
Footnotes
  1. The stock option exercise reported in this Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on June 6, 2019.
  2. The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on June 6, 2019.
  3. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $18.355 to $18.67, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote 3 to this Form 4.
  4. The shares subject to this stock option are fully vested.